Dr Ing Hcf Stock Debt To Equity

P911 Stock   59.22  0.04  0.07%   
Dr Ing hcF fundamentals help investors to digest information that contributes to Dr Ing's financial success or failures. It also enables traders to predict the movement of P911 Stock. The fundamental analysis module provides a way to measure Dr Ing's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dr Ing stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Dr Ing hcF Company Debt To Equity Analysis

Dr Ing's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

 = 

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition

According to the company disclosure, Dr Ing hcF has a Debt To Equity of 0.0%. This is 100.0% lower than that of the Consumer Cyclical sector and 100.0% lower than that of the Auto Manufacturers industry. The debt to equity for all Germany stocks is 100.0% higher than that of the company.

P911 Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dr Ing's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dr Ing could also be used in its relative valuation, which is a method of valuing Dr Ing by comparing valuation metrics of similar companies.
Dr Ing is currently under evaluation in debt to equity category among its peers.

P911 Fundamentals

About Dr Ing Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Dr Ing hcF's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dr Ing using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dr Ing hcF based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in P911 Stock

Dr Ing financial ratios help investors to determine whether P911 Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in P911 with respect to the benefits of owning Dr Ing security.